Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.

Hazell, L.; Pillay, C.; Cornelius, V.; Phillips, R.; Charania, A.; Wason, J.; Cherlin, S.; Savic, S.; Whittington, A.; Neelakantan, P.; Collini, P.; Cook, L.; Willicome, M.; Milojkovic, D.; Kon, OM.; Youngstein, T.; Innes, A.; Thursz, M.; Cooke, GS.; Vergis, N.; Cooper, N.

Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.

All Authors

Hazell, L.

Pillay, C.

Cornelius, V.

Phillips, R.

Charania, A.

Wason, J.

Cherlin, S.

Savic, S.

Whittington, A.

Neelakantan, P.

Show 10 more

LTHT Author

Savic, Sinisa

LTHT Department

Pathology
Clinical Immunology & Allergy

Publication Date

2026

Item Type

Journal Article
Randomized Controlled Trial
Multicenter Study

Subject

COVID-19 , CLINICAL TRIALS AS TOPIC , DRUG THERAPY , HOSPITALISATION , MEN , WOMEN , MIDDLE AGED , AGED , PYRIMIDINES , PYRAZOLES , SEVERITY OF ILLNESS INDEX , ADULT , TREATMENT OUTCOME

Abstract

OBJECTIVES: To determine the safety and efficacy of ruxolitinib (RUX) and fostamatinib (FOS) compared with standard of care (SOC) in patients requiring hospital admission for the treatment of COVID-19 pneumonia. DESIGN: Adaptive multiarm, multistage, randomised, open-label trial (three arm, two stage). SETTING: Five hospitals in England between October 2020 and September 2022. PARTICIPANTS: Hospitalised patients (>=18 years) with COVID-19 pneumonia defined by a modified WHO COVID-19 severity grade of 3 or 4. INTERVENTIONS: Participants were randomly assigned 1:1:1 to receive RUX (10 mg two times per day for 7 days then 5 mg two times per day for 7 days), FOS (150 mg two times per day for 7 days then 100 mg two times per day for 7 days) or SOC. MAIN OUTCOME MEASURES: Primary outcome was development of severe COVID-19 pneumonia (modified WHO severity grade>=5) within 14 days of randomisation. Secondary outcomes included mortality, invasive and non-invasive ventilation, venous thromboembolism, duration of hospital stay, readmissions, inflammatory markers and serious adverse events (SAEs). RESULTS: At stage 1, 181 patients were randomised, with 4 assessed as ineligible post randomisation. FOS was stopped early for futility with 16 participants (27.6%, n=58) developing severe COVID-19 pneumonia compared with 15 (25.0%, n=60) in the SOC arm (adjusted odds ratio (aOR) compared with SOC: 1.12; 95% CI 0.49 to 2.58; p=0.608). RUX progressed to stage 2 but the trial was stopped early due to slow recruitment. At the final analysis, 10 participants (16.1%, n=62) developed severe COVID-19 pneumonia in the RUX arm compared with 15 (24.6%, n=61) in the SOC arm (aOR: 0.63; 95% CI 0.25 to 1.57; p=0.161). Four (7.4%) participants in the FOS arm, none in the RUX arm and three (5.5%) in the SOC arm died within 14 days of randomisation. Infections were the most frequently reported SAE and were numerically higher in the FOS (10, 17.2%) and RUX (10, 16.1%) arms compared with SOC (7, 11.5%). Two unexpected serious adverse reactions occurred in the RUX arm only. CONCLUSIONS: We found no evidence that FOS was superior to SOC for the treatment of COVID-19 pneumonia in patients requiring hospital admission. Due to early stopping, the trial was underpowered to establish RUX's effect in this population. Further study is needed. TRIAL REGISTRATION NUMBER: NCT04581954; EUDRA-CT: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001750-22/GB.